Results 61 to 70 of about 25,866 (210)

Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive‐Stage Small‐Cell Lung Cancer: A Multicenter Retrospective Analysis

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Platinum‐based two‐agent chemotherapy combined with immunotherapy is now the first‐line standard of care for extensive‐stage small cell lung cancer (ES‐SCLC). Further studies are needed to determine whether continuing immunotherapy (IO) can provide benefit in patients whose disease has progressed after first‐line treatment ...
Zhuoran Sun, Yaru Tian, Shuangqing Lu, Jiling Niu, Qingfen Dong, Hui Zhu   +5 more
wiley   +1 more source

Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells. [PDF]

PLoS ONE, 2016
Current treatment of retinoblastoma involves using the maximum dose of chemotherapy that induces tumor control and is tolerated by patients. The impact of dose and schedule on the cytotoxicity of chemotherapy has not been studied.
Ursula Winter, Hebe A Mena, Soledad Negrotto, Eloisa Arana, Guillem Pascual-Pasto, Viviana Laurent, Mariona Suñol, Guillermo L Chantada, Angel M Carcaboso, Paula Schaiquevich   +9 more
doaj   +1 more source

Docking and QSAR Studies of Camptothecin Derivatives as Inhibitor of DNA Topoisomerase-I [PDF]

, 2011
Camptothecin (CPT) is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme Topoisomerase-I (Topo-I) and has shown remarkable anticancer activity in preliminary clinical trials. The major limitation is its low solubility and high adverse reaction.
Dharmendra K. Yadav, Feroz Khan, Santosh K. Srivastava   +2 more
core   +2 more sources

New cell lines expanding the diversity of Ewing sarcoma models

International Journal of Cancer, Volume 158, Issue 3, Page 642-655, 1 February 2026.
What's new? A chromosomal translocation between the EWSR1 and ETS genes is the key oncogenic driver in Ewing sarcoma. EWSR1::FLI1, the most frequent fusion, is subdivided into different fusion types with unclear prognostic relevance. Here, the authors describe the establishment and characterization of four new, intrinsically immortal, patient‐derived ...
Maximilian Kerkhoff, Christiane Schaefer, Wilhelm G. Dirks, Dawid Krzeciesa, Maximilian Bretschneider, Pauline R. Plaumann, Wiebke K. Guder, Arne Streitbürger, Sonja Herter, Heike Peterziel, Ina Oehme, Felina Zahnow, Thomas G. P. Grünewald, Uta Dirksen   +13 more
wiley   +1 more source

Lactone Stabilized by Crosslinked Cyclodextrin Metal-Organic Frameworks to Improve Local Bioavailability of Topotecan in Lung Cancer

Pharmaceutics, 2022
The protection of unstable anticancer molecules and their delivery to lesions are challenging issues in cancer treatment. Topotecan (TPT), a classic cytotoxic drug, is widely used for treating refractory lung cancer.
Ting Xiong, Tao Guo, Yaping He, Zeying Cao, Huipeng Xu, Wenting Wu, Li Wu, Weifeng Zhu, Jiwen Zhang   +8 more
doaj   +1 more source

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G, Matthay, Katherine K, Vo, Kieuhoa T   +2 more
core   +1 more source

Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Natural products play a pivotal role in cancer therapy. They induce cancer cell death by reprogramming four metabolic pathways while precisely targeting the tumor microenvironment and immune cells. These compounds not only leverage novel delivery systems for innovative applications but also demonstrate unique therapeutic efficacy across clinical stages:
Ruimiao Qian, Jun Ge, Ni Fan, Zheng Sun, Chengcheng Zhao, Yujiao Sun, Yingpeng Li, Yunfei Li, Hui Fu   +8 more
wiley   +1 more source

A simulated trial with reinforcement learning for the efficacy of Irinotecan and Ifosfamide versus Topotecan in relapsed, extensive stage small cell lung cancer

BMC Cancer
Objectives Synthetic data may proxy clinical data. At the absence of direct clinical data, this study aimed to compare Irinotecan and Ifosfamide (II) with Topotecan in synthetic, recurrent small cell lung cancer (SCLC) patients within a simulated ...
Hakan Şat Bozcuk, Mehmet Artaç
doaj   +1 more source

A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group

Cancer, Volume 132, Issue 2, 15 January 2026.
Abstract Background Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study ...
Ami V. Desai, Arlene Naranjo, Brian LaBarre, Lulu Chen, Kelly C. Goldsmith, Meaghan P. Granger, Lisa States, Sean G. Green, Mariel Trunzo, Wendy Fitzgerald, Steven G. DuBois, Rochelle Bagatell, Julie R. Park, Araz Marachelian   +13 more
wiley   +1 more source

Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)

Опухоли женской репродуктивной системы, 2014
The efficacy and safety of intravenous topotecan (hycamtin) given in a dose of 4 mg/m2 on days of 1, 8, 15 of a 28-day cycle of its therapy were evaluated in patients with recurrent ovarian cancer (OC).Preliminary analysis of the safety and toxicity of ...
E. G. Novikova, I. A. Korneyeva, E. Yu. Moskovskaya   +2 more
doaj   +1 more source